rivastigmine Oral Solution

Brand(s)
Exelon
Category(s)
prescription
SPL Type(s)
Human Prescription
Oldest Current Product
2000-04-30
License(s)
NDA
RxNORM
ORAL SOLUTION\RIVASTIGMINE
FDAOB
ORAL\SOLUTION\RIVASTIGMINE TARTRATE
SPL Active
ORAL\SOLUTION\RIVASTIGMINE TARTRATE
SPL Moiety
ORAL\SOLUTION\RIVASTIGMINE

product(s) by strength(s)

invalid application product(s)

#idbrandcategorylabelerfirst marketedlast marketedactive ingredient(s)routedose formapplicationspl
1000780339ExelonNDANovartis Pharmaceuticals Corporation2000-04-302014-06-30RIVASTIGMINE TARTRATEORALSOLUTIONNDA021025f1e28b44-3897-4788-9659-f5d6bce4d91e

application(s)

#idtitledeprecatedapplicantapprovedapproved drug
1NDA021025EXELONTrueNOVARTIS PHARMACEUTICALS CORP2000-04-21NDA021025_001

application drug(s)

#idcategory/deprecatedingredient strength(s)routedose formrldapprovedapplication
1NDA021025_001discontinuedRIVASTIGMINE TARTRATE (EQ 2MG BASE/ML)ORALSOLUTIONFalse2000-04-21EXELON

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)in other drug docs
1f1e28b44-3897-4788-9659-f5d6bce4d91e (view SPL)These highlights do not include all the information needed to use EXELON safely and effectively. See full prescribing information for EXELON. EXELON (rivastigmine tartrate) capsules, for oral use EXELON (rivastigmine tartrate) oral solution Initial U.S. Approval: 2000prescriptionHuman PrescriptionNovartis Pharmaceuticals Corporation2015-02-0314000780339, 000780323, 000780324, 000780325, 000780326rivastigmine Oral Capsule

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII